Arval Service (A3K9NF) News

Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection

Announces “Stalking Horse” Agreement for the Sale of Zokinvy® (lonafarnib) Patient Access to Zokinvy® to...

Form 8-K - Current report

Form 8-K - Current report

Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan

Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome...

Form 8-K - Current report

Form 8-K - Current report

Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split

Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split PR Newswire PALO ALTO, Calif., Jan. 4...

Form DEF 14A - Other definitive proxy statements

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form PRE 14A - Other preliminary proxy statements

Form SC 13D - General statement of acquisition of beneficial ownership

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update PR...